# Metastatic Breast Cancer FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/metastatic-breast-cancer

> 6 upcoming FDA catalysts in metastatic Breast Cancer: sacituzumab govitecan-hziy (GILD) on December 2026 (primary completion); sacituzumab govitecan-hziy (GILD) on Dec 2026 to Mar 2027 (topline data readout); lasofoxifene in combination with abemaciclib (LONA) on April 2027 (primary completion); lasofoxifene in combination with abemaciclib (LONA) on Apr to Jul 2027 (topline data readout); and 2 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| December 2026 | [Sacituzumab govitecan-hziy primary completion](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy) | GILD | Metastatic Breast Cancer | scheduled | "NCT04639986 (Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04639986)) |
| Dec 2026 to Mar 2027 | [Sacituzumab govitecan-hziy topline data readout](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy) | GILD | Metastatic Breast Cancer | scheduled | "NCT04639986 (Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04639986)) |
| April 2027 | [Lasofoxifene in combination with abemaciclib primary completion](https://sec-api.dev/pdufa/lasofoxifene-in-combination-with-abemaciclib) | LONA | Metastatic Breast Cancer | scheduled | "NCT05696626 (Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-04 (ESTIMATED); Lead Sponsor LeonaBio." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05696626)) |
| Apr to Jul 2027 | [Lasofoxifene in combination with abemaciclib topline data readout](https://sec-api.dev/pdufa/lasofoxifene-in-combination-with-abemaciclib) | LONA | Metastatic Breast Cancer | scheduled | "NCT05696626 (Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-04 (ESTIMATED); Lead Sponsor LeonaBio." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05696626)) |
| May to Aug 2027 | [WELIREG® (belzutifan) topline data readout](https://sec-api.dev/pdufa/belzutifan) | MRK | Metastatic Breast Cancer | scheduled | "NCT06428396 (Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05-05 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06428396)) |
| May 2027 | [WELIREG® (belzutifan) primary completion](https://sec-api.dev/pdufa/belzutifan) | MRK | Metastatic Breast Cancer | scheduled | "NCT06428396 (Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05-05 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06428396)) |

## Drugs

- [Sacituzumab govitecan-hziy](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy) (GILD)
- [Lasofoxifene in combination with abemaciclib](https://sec-api.dev/pdufa/lasofoxifene-in-combination-with-abemaciclib) (LONA)
- [WELIREG® (belzutifan)](https://sec-api.dev/pdufa/belzutifan) (MRK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/metastatic-breast-cancer.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Metastatic Breast Cancer FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/metastatic-breast-cancer

```bibtex
@misc{secapidev_indications_metastatic_breast_cancer_20261116,
  title        = {Metastatic Breast Cancer FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/metastatic-breast-cancer}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_metastatic_breast_cancer_20261116","title":"Metastatic Breast Cancer FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/metastatic-breast-cancer","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
